Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment Efficacy for Drug Abuse and AIDS Prevention - 2

This study has been completed.
Mclean Hospital
Information provided by (Responsible Party):
National Institute on Drug Abuse (NIDA) Identifier:
First received: September 20, 1999
Last updated: April 30, 2013
Last verified: December 2002

The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.

Condition Intervention Phase
Cocaine-Related Disorders
Heroin Dependence
Drug: Buprenorphine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Treatment Efficacy for Drug Abuse and AIDS Prevention

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Estimated Enrollment: 0

Ages Eligible for Study:   26 Years to 41 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000211

United States, Massachusetts
McLean Hospital, Dept. of Psychiatry
Belmont, Massachusetts, United States, 2178
Sponsors and Collaborators
Mclean Hospital
Principal Investigator: Jack Mendelson, M.D. Mclean Hospital
  More Information

No publications provided

Responsible Party: National Institute on Drug Abuse (NIDA) Identifier: NCT00000211     History of Changes
Other Study ID Numbers: NIDA-06116-2, R18-06116-2
Study First Received: September 20, 1999
Last Updated: April 30, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Heroin Dependence
Chemically-Induced Disorders
Mental Disorders
Opioid-Related Disorders
Substance-Related Disorders
Analgesics, Opioid
Central Nervous System Agents
Central Nervous System Depressants
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 25, 2014